A Randomized, Partially-blind Study on the Safety, Tolerability and Effect on Virological Response of Treatment With the HCV Protease Inhibitor RO5190591 in Combination With Pegasys and Copegus, Versus Pegasys and Copegus Alone, in Treatment-Naïve Patients With Hepatitis C Genotype 1 Virus Infectio
Overview
- Phase
- Phase 2
- Intervention
- Pegasys
- Conditions
- Hepatitis C, Chronic
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 229
- Primary Endpoint
- Sustained virological response
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
This 2 part study will evaluate the efficacy and safety of 12 and 24 weeks treatment with RO5190591 (danoprevir) in combination with Pegasys and Copegus, compared to Pegasys and Copegus alone, in treatment-naive patients with chronic hepatitis C genotype 1 virus infection.In Part 1 of the study, patients will be randomized to receive either 1) RO5190591 300mg po every 8 hours, 2) RO5190591 600mg po every 12 hours, 3) RO5190591 900mg po every 12 hours or 4) placebo, in combination with standard doses of Pegasys and Copegus. If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive either 1) RO5190591 300mg po every 8 hours or 600mg po every 12 hours or 900mg po every 12 hours or 2)placebo, in combination with standard doses of Pegasys and Copegus. The anticipated time on study treatment is 24-48 weeks, and the target sample size is 100-500 individuals.
Investigators
Eligibility Criteria
Inclusion Criteria
- •adult patients, \>=18 years of age;
- •chronic hepatitis C, genotype 1;
- •treatment-naive.
Exclusion Criteria
- •liver cirrhosis and other forms of liver disease;
- •HIV infection;
- •hepatocellular cancer;
- •cardiac disease.
Arms & Interventions
Part 1: RO5190591 900mg po
RO5190591 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
Intervention: Pegasys
Part 1: Placebo
Placebo in combination with standard doses of Pegasys and Copegus.
Intervention: Copegus
Part 1: RO5190591 300mg po
RO5190591 300mg po every 8 hours in combination with standard doses of Pegasys and Copegus.
Intervention: RO5190591 (Danoprevir)
Part 1: RO5190591 600mg po
RO5190591 600mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
Intervention: Copegus
Part 1: Placebo
Placebo in combination with standard doses of Pegasys and Copegus.
Intervention: Pegasys
Part 1: Placebo
Placebo in combination with standard doses of Pegasys and Copegus.
Intervention: Placebo
Part 1: RO5190591 300mg po
RO5190591 300mg po every 8 hours in combination with standard doses of Pegasys and Copegus.
Intervention: Copegus
Part 1: RO5190591 300mg po
RO5190591 300mg po every 8 hours in combination with standard doses of Pegasys and Copegus.
Intervention: Pegasys
Part 1: RO5190591 600mg po
RO5190591 600mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
Intervention: Pegasys
Part 1: RO5190591 600mg po
RO5190591 600mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
Intervention: RO5190591 (Danoprevir)
Part 1: RO5190591 900mg po
RO5190591 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
Intervention: Copegus
Part 1: RO5190591 900mg po
RO5190591 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
Intervention: RO5190591 (Danoprevir)
Part 2: Placebo
If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive placebo in combination with standard doses of Pegasys and Copegus.
Intervention: Copegus
Part 2: Placebo
If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive placebo in combination with standard doses of Pegasys and Copegus.
Intervention: Pegasys
Part 2: Placebo
If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive placebo in combination with standard doses of Pegasys and Copegus.
Intervention: Placebo
Part 2: RO5190591 300mg po
If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive RO5190591 300mg po every 8 hours or 600mg po every 12 hours or 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
Intervention: Copegus
Part 2: RO5190591 300mg po
If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive RO5190591 300mg po every 8 hours or 600mg po every 12 hours or 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
Intervention: Pegasys
Part 2: RO5190591 300mg po
If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive RO5190591 300mg po every 8 hours or 600mg po every 12 hours or 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
Intervention: RO5190591 (Danoprevir)
Outcomes
Primary Outcomes
Sustained virological response
Time Frame: 24 weeks after end of treatment
Secondary Outcomes
- Virological response over time(At 2- to 6-weekly intervals throughout study; at end of treatment; 12 weeks post-treatment)
- Adverse events; laboratory parameters(Throughout study, laboratory parameters every 2 to 6 weeks)